Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group

Stout AP (1954) Juvenile fibromatoses. Cancer 7(5):953–978 Mashiah J, Hadj-Rabia S, Dompmartin A, Harroche A, Laloum-Grynberg E, Wolter M et al (2014) Infantile myofibromatosis: a series of 28 cases. J Am Acad Dermatol 71(2):264–270 Cheung YH, Gayden T, Campeau PM, LeDuc CA, Russo D, Nguyen VH et al (2013) A recurrent PDGFRB mutation causes familial infantile myofibromatosis. Am J Hum Genet 92(6):996–1000 Martignetti JA, Tian L, Li D, Ramirez MC, Camacho-Vanegas O, Camacho SC et al (2013) Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis. Am J Hum Genet 92(6):1001–1007 Weller JM, Keil VC, Gielen GH, Herrlinger U, Schafer N (2019) PDGRFB mutation-associated myofibromatosis: response to targeted therapy with imatinib. Am J Med Genet A 179(9):1895–1897 Al Qawahmed R, Sawyer SL, Vassilyadi M, Qin W, Boycott KM, Michaud J (2019) Infantile myofibromatosis with intracranial extradural involvement and PDGFRB mutation: a case report and review of the literature. Pediatr Dev Pathol 22(3):258–264 Dachy G, de Krijger RR, Fraitag S, Theate I, Brichard B, Hoffman SB et al (2019) Association of PDGFRB mutations with pediatric myofibroma and myofibromatosis. JAMA Dermatol 155:946 Mudry P, Slaby O, Neradil J, Soukalova J, Melicharkova K, Rohleder O et al (2017) Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene. BMC Cancer 17(1):119 Lepelletier C, Al-Sarraj Y, Bodemer C, Shaath H, Fraitag S, Kambouris M et al (2017) Heterozygous PDGFRB mutation in a three-generation family with autosomal dominant infantile myofibromatosis. Acta Derm Venereol 97(7):858–859 Murray N, Hanna B, Graf N, Fu H, Mylene V, Campeau PM et al (2017) The spectrum of infantile myofibromatosis includes both non-penetrance and adult recurrence. Eur J Med Genet 60(7):353–358 Arts FA, Chand D, Pecquet C, Velghe AI, Constantinescu S, Hallberg B et al (2016) PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib. Oncogene 35(25):3239–3248 Ito N, Watanabe S, Mishima H, Kinoshita A, Okada M, Moriuchi H et al (2019) A mutation in PDGFRB in a family with infantile myofibromatosis. Acta Med Nagasaki 63:49–53 Linhares ND, Freire MC, Cardenas RG, Bahia M, Puzenat E, Aubin F et al (2014) Modulation of expressivity in PDGFRB-related infantile myofibromatosis: a role for PTPRG? Genet Mol Res 13(3):6287–6292 Ortiz E, Kochhar A, Chandrasekar I (2020) Invasive myofibromatosis with visceral involvement in a term newborn: a case report. Am J Pediatr 6(2):173–177 Arts FA, Sciot R, Brichard B, Renard M, de Rocca SA, Dachy G et al (2017) PDGFRB gain-of-function mutations in sporadic infantile myofibromatosis. Hum Mol Genet 26(10):1801–1810 Agaimy A, Bieg M, Michal M, Geddert H, Markl B, Seitz J et al (2017) Recurrent somatic PDGFRB mutations in sporadic infantile/solitary adult myofibromas but not in angioleiomyomas and myopericytomas. Am J Surg Pathol 41(2):195–203 Vikkula M, Boon LM, Carraway KL 3rd, Calvert JT, Diamonti AJ, Goumnerov B et al (1996) Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 87(7):1181–1190 Hassan M, Butler E, Wilson R, Roy A, Zheng Y, Liem P et al (2019) Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib. Cold Spring Harb Mol Case Stud. 5(5):a0004440 Flynn JP, Gerriets V. Imatinib. StatPearls. Treasure Island (FL)2020. Pond D, Arts FA, Mendelsohn NJ, Demoulin JB, Scharer G, Messinger Y (2018) A patient with germ-line gain-of-function PDGFRB pN666H mutation and marked clinical response to imatinib. Genet Med 20(1):142–150 Millot F, Guilhot J, Baruchel A, Petit A, Leblanc T, Bertrand Y et al (2014) Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. Eur J Cancer 50(18):3206–3211 Minatogawa M, Takenouchi T, Tsuyusaki Y, Iwasaki F, Uehara T, Kurosawa K et al (2017) Expansion of the phenotype of Kosaki overgrowth syndrome. Am J Med Genet A 173(9):2422–2427 Takenouchi T, Yamaguchi Y, Tanikawa A, Kosaki R, Okano H, Kosaki K (2015) Novel overgrowth syndrome phenotype due to recurrent de novo PDGFRB mutation. J Pediatr 166(2):483–486 Johnston JJ, Sanchez-Contreras MY, Keppler-Noreuil KM, Sapp J, Crenshaw M, Finch NA et al (2015) A point mutation in PDGFRB causes autosomal-dominant Penttinen syndrome. Am J Hum Genet 97(3):465–474 Zhang Z, Zheng S, Zheng S, Wang Y, Xu XG, Gao XH et al (2018) Premature aging syndrome, penttinen type: report of a Chinese case with a PDGFRB mutation. Acta Derm Venereol 98(9):912–913 Guimier A, Gordon CT, Hully M, Blauwblomme T, Minard-Colin V, Bole-Feysot C et al (2019) A novel de novo PDGFRB variant in a child with severe cerebral malformations, intracerebral calcifications, and infantile myofibromatosis. Am J Med Genet A 179(7):1304–1309 Karasozen Y, Osbun JW, Parada CA, Busald T, Tatman P, Gonzalez-Cuyar LF et al (2019) Somatic PDGFRB activating variants in fusiform cerebral aneurysms. Am J Hum Genet 104(5):968–976 Wenger TL, Bly RA, Wu N, Albert CM, Park J, Shieh J, et al (2020) Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy. Am J Med Genet A Foster A, Chalot B, Antoniadi T, Schaefer E, Keelagher R, Ryan G et al (2020) Kosaki overgrowth syndrome: a novel pathogenic variant in PDGFRB and expansion of the phenotype including cerebrovascular complications. Clin Genet 98:19 Zarate YA, Boccuto L, Srikanth S, Pauly R, Ocal E, Balmakund T et al (2019) Constitutive activation of the PI3K-AKT pathway and cardiovascular abnormalities in an individual with Kosaki overgrowth syndrome. Am J Med Genet A 179(6):1047–1052 Nicolas G, Guillin O, Borden A, Bioux S, Lefaucheur R, Hannequin D. Psychosis revealing familial idiopathic basal ganglia calcification. Gen Hosp Psychiatry. 2013;35(5):575 e3–5. Antonescu CR, Sung YS, Zhang L, Agaram NP, Fletcher CD (2017) Recurrent SRF-RELA fusions define a novel subset of cellular myofibroma/myopericytoma: a potential diagnostic pitfall with sarcomas with myogenic differentiation. Am J Surg Pathol 41(5):677–684 Hausbrandt PA, Leithner A, Beham A, Bodo K, Raith J, Windhager R (2010) A rare case of infantile myofibromatosis and review of literature. J Pediatr Orthop B 19(1):122–126 Argenta AE, Chen W, Davis A, Losee JE, Davit A, Grunwaldt L (2015) A review of eight unusual pediatric skin and soft-tissue lesions: diagnosis, workup, and treatment. J Plast Reconstr Aesthet Surg 68(12):1637–1646 Levine E, Freneaux P, Schleiermacher G, Brisse H, Pannier S, Teissier N et al (2012) Risk-adapted therapy for infantile myofibromatosis in children. Pediatr Blood Cancer 59(1):115–120 Kim KH, Park YN, Joo HJ, Lee KG, Park C, Kim DS (1989) Infantile myofibromatosis. Yonsei Med J 30(4):376–382 Inoue M, Tanaka S, Nakatomi H, Takayanagi S, Takahashi M, Tanaka M et al (2016) Intracranial infantile myofibromatosis mimicking malignant brain tumor: a case report and literature review. World Neurosurg 93(487):e15–20 Linos K, Carter JM, Gardner JM, Folpe AL, Weiss SW, Edgar MA (2014) Myofibromas with atypical features: expanding the morphologic spectrum of a benign entity. Am J Surg Pathol 38(12):1649–1654 Coffin C, Boccon-Gibod L (2004) Fibroblastic-myofibroblastic proliferations of childhood and adolescents. Ann Pathol 24(6):605–620 Wiswell TE, Sakas EL, Stephenson SR, Lesica JJ, Reddoch SR (1985) Infantile myofibromatosis. Pediatrics 76(6):981–984 Brasseur B, Chantrain CF, Godefroid N, Sluysmans T, Anslot C, Menten R et al (2010) Development of renal and iliac aneurysms in a child with generalized infantile myofibromatosis. Pediatr Nephrol 25(5):983–986 Frezin J, Fusaro F, Reding R, Godefroid N (2015) Kidney transplantation in infantile myofibromatosis and fibromuscular dysplasia: a case report. J Med Case Rep 9:270 Wright C, Corbally MT, Hayes R, McDermott MB (2004) Multifocal infantile myofibromatosis and generalized fibromuscular dysplasia in a child: evidence for a common pathologic process? Pediatr Dev Pathol 7(4):385–390 McIntosh WA, Kassner GW, Murray JF (1985) Fibromatosis and fibrosarcoma of the larynx and pharynx in an infant. Arch Otolaryngol 111(7):478–480 Beck JC, Devaney KO, Weatherly RA, Koopmann CF Jr, Lesperance MM (1999) Pediatric myofibromatosis of the head and neck. Arch Otolaryngol Head Neck Surg 125(1):39–44 Stanford D, Rogers M (2000) Dermatological presentations of infantile myofibromatosis: a review of 27 cases. Aust J Dermatol 41(3):156–161 Weaver MS, Navid F, Huppmann A, Meany H, Angiolillo A (2015) Vincristine and dactinomycin in infantile myofibromatosis with a review of treatment options. J Pediatr Hematol Oncol 37(3):237–241 Orbach D, Brennan B, Bisogno G, Van Noesel M, Minard-Colin V, Daragjati J et al (2017) The EpSSG NRSTS 2005 treatment protocol for desmoid-type fibromatosis in children: an international prospective case series. Lancet Child Adolesc Health 1(4):284–292 Skapek SX, Ferguson WS, Granowetter L, Devidas M, Perez-Atayde AR, Dehner LP et al (2007) Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol 25(5):501–506 Sparber-Sauer M, Seitz G, von Kalle T, Vokuhl C, Leuschner I, Scheer M et al (2018) Systemic therapy of aggressive fibromatosis in children and adolescents: report of the Cooperative Weichteilsarkom Studiengruppe (CWS). Pediatr Blood Cancer 65(5):e26943 Pignolo RJ, Wang H, Kaplan FS (2019) Fibrodysplasia ossificans progressiva (FOP): a segmental progeroid syndrome. Front Endocrinol (Lausanne) 10:908 Tang ER, Khalatbari H, Parisi MT (2019) Utility of 18F-FDG PET/CT in infantile myofibromatosis. Clin Nucl Med Merlin MS, Le Rouzic MA, Vignaud JM, Scheid P (2018) A rare case of neonatal-onset infantile myofibromatosis with metastatic recurrence in adulthood. Arch Clin Cases 5(2):32–36